SPRC

SPRC

USD

SciSparc Ltd. Ordinary Shares

$3.060-0.190 (-5.846%)

Preço em tempo real

Healthcare
Biotecnologia
Israel

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$3.250

Máximo

$3.320

Mínimo

$3.060

Volume

0.06M

Fundamentos da empresa

Capitalização de mercado

5.0M

Setor

Biotecnologia

País

Israel

Estatísticas de negociação

Volume médio

4.79M

Bolsa de valores

NCM

Moeda

USD

Faixa de 52 semanas

Mínimo $1.75Atual $3.060Máximo $37.59

Notícias relacionadas

GlobeNewswire

N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers

Neve Yarak, Israel, Oct. 30, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model,

Ver mais
N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers
GlobeNewswire

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

TEL AVIV, Israel, Oct. 24, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders

Ver mais
SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio
GlobeNewswire

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies

Ver mais
SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
GlobeNewswire

N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Neve Yarak, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model,

Ver mais
N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
GlobeNewswire

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

According to the agreement, SciSparc's pharmaceuticals assets and equity stake in SciSparc Nutraceuticals Inc. are valued at approximately US$11.6 million TEL AVIV, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) -- SciSparc

Ver mais
SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.